Publications by authors named "Mark Cragg"

Claim this Profile
A
A "Function-First" Approach to Identify Regulatory T cell-Targeting Antibodies for Immunotherapy.
Kirstie L S Cleary, Monika Semmrich, Linda Martensson, Ulla-Carin Tornberg, David Ermert, Mark S Cragg

Cancer Immunol Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Harnessing multivalency and FcγRIIB engagement to augment anti-CD27 immunotherapy.
Marcus A Widdess, Anastasia Pakidi, Hannah J Metcalfe, H T Claude Chan, Tatyana Inzhelevskaya, Mark S Cragg

Nat Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial.
Lara E Buermann, Louise Stanton, Matthew J J Rose-Zerilli, Kerensa Thorne, Adam Coleman, Mark S Cragg

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis.
Lara V Graham, Ludmila Horehajova, Marco V Haselager, Jack G Fisher, Jamie Lee Roos, Mark S Cragg

Immunother Adv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ETS-family transcription factor PU.1 is a critical regulator of the inhibitory Fcγ receptor IIB expression in humans.
Matthew J Carter, Yury D Bogdanov, Rosanna C Smith, Kerry L Cox, Sarah Frampton, Mark S Cragg

J Immunol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autophagy is an upstream mediator of chromatin dynamics in normal and autoimmune germinal center B cells.
Marta C Sallan, Filip Filipsky, Christina H Shi, Elena Pontarini, Manuela Terranova-Barberio, Mark S Cragg

J Clin Invest· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-guided disulfide engineering restricts antibody conformation to elicit TNFR agonism.
Isabel G Elliott, Hayden Fisher, H T Claude Chan, Tatyana Inzhelevskaya, C Ian Mockridge, Mark S Cragg

Nat Commun· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The complement system in clinical oncology: Applications, limitations and challenges.
Daniel Ajona, Mark S Cragg, Ruben Pio

Semin Immunol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic targeting of tumour-associated macrophage receptors.
Rosa Gomes Alves Martins, Mehmet M Tekin, Mark S Cragg, Ali Roghanian

Immunother Adv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs.
Alexander P Simpson, Robert J Oldham, Kerry L Cox, Martin C Taylor, Sonya James, Mark S Cragg

Clin Exp Immunol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fc gamma receptors: Their evolution, genomic architecture, genetic variation, and impact on human disease.
Sarah Frampton, Rosanna Smith, Lili Ferson, Jane Gibson, Edward J Hollox, Mark S Cragg

Immunol Rev· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Downhill running does not alter blood C1q availability or complement-dependent cytotoxicity of therapeutic monoclonal antibodies against haematological cancer cell lines in vitro.
Harrison D Collier-Bain, Frankie F Brown, Adam J Causer, Lois Ross, Daniela Rothschild-Rodriguez, Mark S Cragg

Sci Rep· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies.
Lara V Graham, Jack G Fisher, Amber D P Doyle, Ben Sale, Luis Del Rio, Mark S Cragg

Front Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations.
Jane E Willoughby, Lang Dou, Sabyasachi Bhattacharya, Heather Jackson, Laura Seestaller-Wehr, Mark S Cragg

J Immunother Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-talk between ILC2 and Gata3 T locally constrains adaptive type 2 immunity.
Julie Stockis, Thomas Yip, Julia Moreno-Vicente, Oliver Burton, Youhani Samarakoon, Mark S Cragg

Sci Immunol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?
Kavina Shah, Maria Leandro, Mark Cragg, Florian Kollert, Franz Schuler

Clin Exp Immunol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACE2 decoy Fc-fusions and bi-specific killer engager (BiKEs) require Fc engagement for efficacy against SARS-CoV-2.
Jenna K Dick, Dustin Hicks, Venkatramana D Krishna, Jules A Sangala, Benjamin T Zandstra, Mark S Cragg

bioRxiv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges.
Sean H Lim, Stephen A Beers, Aymen Al-Shamkhani, Mark S Cragg

Clin Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo.
Harrison D Collier-Bain, Annabelle Emery, Adam J Causer, Frankie F Brown, Rebecca Oliver, Mark S Cragg

Brain Behav Immun· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity.
Paul T Kennedy, Emma L Saulters, Andrew D Duckworth, Yeong Jer Lim, John F Woolley, Mark S Cragg

Mol Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human leukocyte immunoglobulin-like receptors in health and disease.
Silvia Redondo-García, Christopher Barritt, Charys Papagregoriou, Muchaala Yeboah, Björn Frendeus, Mark S Cragg

Front Immunol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy.
Falk Nimmerjahn, Gestur Vidarsson, Mark S Cragg

Nat Immunol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression.
Jack G Fisher, Amber D P Doyle, Lara V Graham, Shreyanshi Sonar, Ben Sale, Mark S Cragg

Leukemia· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Special Issue "Advances in Genome Regulation in Cancer".
Jekaterina Erenpreisa, Alessandro Giuliani, Mark Steven Cragg

Int J Mol Sci· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy.
Falk Nimmerjahn, Gestur Vidarsson, Mark S Cragg

Nat Immunol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis